Treatment of patients over 64 years of age with type 2 diabetes: Experience from nateglinide pooled database retrospective analysis

Diabetes Care

Volumn 26, Issue 7, 2003, Pages 2075-2080

  Del Prato, Stefano ^a   Heine, Robert J ^b   Keilson, Leonard ^c   Guitard, Christiane ^d   Shen, Sharon G ^d   Emmons, Rebecca P ^d  

^a UNIVERSITY OF PISA   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAINE MEDICAL CENTER   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; METFORMIN; NATEGLINIDE; PLACEBO; ANTIDIABETIC AGENT; CYCLOHEXANE DERIVATIVE; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; PHENYLALANINE;

AGED; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; BLOOD; BODY MASS; DIABETIC ANGIOPATHY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; META ANALYSIS; METABOLISM; RETROSPECTIVE STUDY;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; COMORBIDITY; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PHENYLALANINE; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 2142769878     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.7.2075     Document Type: Article

References (28)

1. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H, Thompson TJ: Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 24:1936-1940, 2001
2. Rosenstock J: Management of type 2 diabetes mellitus in the elderly: special considerations. Drugs Aging 18:31-44, 2001
3. Jennings PE: Oral hypoglycaemics: considerations in older patients with non-insulin-dependent diabetes mellitus. Drugs Aging 10:323-331, 1997
4. Graal MB, Wolfenbuttel BHR: The use of sulfonylureas in the elderly. Drugs Aging 15:471-481, 1999
5. Meneilly GS, Tessier D: Diabetes in elderly adults. J Gerontol 56A:M5-M13, 2001
6. Krentz AJ, Ferner RE, Bailey CJ: Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 11:223-241, 1994
7. Yap WS, Peterson GM, Vial JH, Randall CT, Greenaway TM: Review of management of type 2 diabetes. J Clin Pharm Ther 23:457-465, 1998
8. Varas-Lorenzo C, Rueda de Castro AM, Maguire A, Miret M, Blanch C: Cardiovascular comorbidity in the U.S. elderly population with renal and glucose metabolism impairment: the Third National Health and Nutrition Examination Survey. Pharmacoepidemiol Drug Saf 11:S53, 2002
9. Holstein A, Nahrwold D, Hinze S, Egberts EH: Contra-indications to metformin therapy are largely disregarded. Diabet-Med 16:692-696, 1999
10. Davidson MB, Peters AL: An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 120:99-110, 1997
11. Harrower AD: Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 31:111-119, 1996
12. Van Staa T, Agenhain L, Monette J: Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 50:735-741, 1997
13. Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y: Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Intern Med 159:281-284, 1999
14. Pratley RE, Foley JE, Dunning BE: Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharm Des 7:1375-1397, 2001
15. Hu S, Wang S, Fanelli B, Bell PA, Dunning BE, Geisse S, Schmitz R, Boettcher BR: Pancreatic β-cell KATP: channel activity and membrane binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J Pharm Exp Ther 293:444-452, 2000
16. Keilson L, Mather S, Walter YH, Subramanian S, McLeod JF: Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes. J Clin Endocrinol Metab 85:1081-1086, 2000
17. Hanefeld M, Bouter KP, Dickinson S, Guitard C: Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and meal glycemia. Diabetes Care 23:202-207, 2000
18. Choudhury S, Hirschberg Y, Filipek R, Lasseter K, McLeod JF: Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis. J Clin Phamacol 40: 634-640, 2000
19. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S: Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23:1660-1665, 2000
20. Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE: Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 24:983-988, 2001
21. Marre M, Van Gaal L, Usadel KH, Ball M, Whatmough I, Guitard C: Nateglinide improves glycemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab 4:177-186, 2002
22. Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D: Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab 87:4171-4176, 2002
23. Rosenstock J, Gatlin MR, Shen SG, Foley JE: Combination therapy with nateglinide and a thiazolidindione improves glycemic control in type 2 diabetes. Diabetes Care 25:1529-1533, 2002
24. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
25. Sampson MJ, Drury PL: Acurate estimation of glomerular filtration rates in diabetic nephropathy from age, body weight, and serum creatinine. Diabetes Care 15: 609-612, 1992
26. Papaioannou A, Ray JG, Ferko NC, Clarke JA, Campbell G, Adachi J: Estimation of creatinine clearance in elderly persons in long-term care facilities. Am J Med 111: 569-573, 2001
27. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position statement). Diabetes Care 24 (Suppl. 1):S33-S43, 2001
28. Barrett-Connor E, Ferrari A: Isolated post-challenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. Diabetes Care 21:1236-1239, 1998